Vyne Therapeutics

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$84
$121
$198
$98
Gross Profit
84
121
198
98
EBITDA
-12,770
-13,091
-9,395
-7,380
EBIT
-10,396
-6,603
Net Income
-12,022
-12,157
-9,395
-6,241
Net Change In Cash
84
121
198
98
Free Cash Flow
-9,116
-8,510
-8,481
-7,982
Cash
19,926
16,272
29,655
19,119
Basic Shares
42,588
42,587
42,586
42,581

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$501
$424
$477
$14,755
Gross Profit
501
424
477
11,407
EBITDA
-43,633
-29,258
-34,223
-38,937
EBIT
-43,637
-29,003
-34,295
-39,046
Net Income
-39,834
-28,452
-33,945
-73,329
Net Change In Cash
501
424
477
14,755
Free Cash Flow
-34,089
-25,341
-29,200
-56,367
Cash
19,926
30,620
30,908
42,250
Basic Shares
42,589
10,273
3,185
2,858

Earnings Calls

Quarter EPS
2024-12-31
-$0.28
2024-09-30
-$0.29
2024-06-30
-$0.22
2024-03-31
-$0.15